Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Mark I. Furman"'
Publikováno v:
Current Protocols in Cytometry
In inflammatory and thrombotic syndromes, platelets aggregate with circulating leukocytes, especially monocytes and neutrophils. This leukocyte-platelet aggregate formation is initiated primarily through platelet surface expression of P-selectin (CD6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e72b733a6cc0711fee4cf68fb486ecc
https://doi.org/10.1002/cpcy.8
https://doi.org/10.1002/cpcy.8
Autor:
Mark I. Furman, Alan D. Michelson, Marc R. Barnard, Shilpa Rahangdale, Victor Novack, Atul Malhotra, Andrew L. Frelinger, KE Stevenson, Susie Yim Yeh
Publikováno v:
Journal of Clinical Sleep Medicine. :172-178
Objectives:Literature regarding platelet function in obstructive sleep apnea (OSA) has considerable limitations. Given the central role of platelets in atherothrombosis and the known cardiovascular...
Autor:
Hongqiu Yang, Mark I. Furman, Craig J. Reist, Kenneth W. Mahaffey, Richard C. Becker, Neal S. Kleiman, John L. Petersen, A. Michael Lincoff, Ali J. Marian, Stanley L. Hazen
Publikováno v:
Journal of Thrombosis and Thrombolysis. 31:146-153
Heparin compounds, to include fractionated and unfractionated preparations, exert both antithrombotic and antiinflammatory effects through combined inhibition of factor Xa and thrombin. The contribution of modulated platelet activity in vivo is less
Autor:
Andrew L. Frelinger, YouFu Li, Marc R. Barnard, Marsha L. Fox, Mark I. Furman, Douglas J. Christie, Matthew D. Linden, Alan D. Michelson
Publikováno v:
Circulation. 120:2586-2596
Background— Poor clinical outcome in aspirin-treated patients has been termed aspirin resistance and may result from inadequate inhibition of platelet cyclooxygenase-1 (COX-1) by aspirin. The objectives of this study were to determine prospectively
Autor:
Alvaro Avezum, Frans Van de Werf, Keith A.A. Fox, Kim A. Eagle, Joel M. Gore, Phillippe Gabriel Steg, Shaun G. Goodman, Mark I. Furman, Gilles Montalescot, Wei Huang
Publikováno v:
European Heart Journal. 30:321-329
Aims To assess mortality after drug-eluting stent (DES) or bare-metal stent (BMS) for ST-segment elevation myocardial infarction (STEMI). Methods and results In this multinational registry, 5093 STEMI patients received a stent: 1313 (26%) a DES and 3
Publikováno v:
Nursing Critical Care. 3:40-48
Autor:
YouFu Li, Marc R. Barnard, Joseph A. Jakubowski, Inge Tarnow, Alan D. Michelson, Mark I. Furman, Marsha L. Fox, Matthew D. Linden, Kenneth J. Winters, Atsuhiro Sugidachi, Andrew L. Frelinger
Publikováno v:
Journal of Thrombosis and Haemostasis. 6:359-365
Summary. Background: Prasugrel is a novel antiplatelet prodrug of the same thienopyridine class as clopidogrel and ticlopidine. Metabolism of prasugrel generates the active metabolite R-138727, an antagonist of the platelet P2Y12 adenosine diphosphat
Autor:
Christopher P. Cannon, Stephen D. Wiviott, Mark I. Furman, Eric R. Bates, Paul A. Gurbel, Deepak L. Bhatt, Peter B. Berger, Dominick J. Angiolillo, Eric D. Peterson, Eugene Braunwald, Alan D. Michelson
Publikováno v:
Clinical Cardiology. 31:I21-I27
Hyporesponsiveness, or resistance, to antiplatelet therapy may be a major contributor to poorer outcomes among cardiac patients and may be attributed to an array of mechanisms—both modifiable and unmodifiable. Recent evidence has uncovered clinical
Publikováno v:
Men in Nursing. 2:26-34
Publikováno v:
Basic Research in Cardiology. 102:274-278
Growing evidence from experimental models suggests that relief of myocardial ischemia in a stuttering manner (i.e., 'postconditioning' [PostC] with brief cycles of reperfusion-reocclusion) limits infarct size. However, the potential clinical efficacy